← All trials
NCT06925737
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 13, 2025
- Primary completion
- Jun 26, 2028
- Completion date
- Jan 6, 2031
- First posted
- Apr 13, 2025
- Last posted
- Oct 20, 2025
- Enrollment
- 1440
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- MerckLead sponsor
- MerckOfficial
- Daiichi SankyoCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.